BIA
CTMX icon

Bell Investment Advisors’s CytomX Therapeutics CTMX Stock Holding History

Bell Investment Advisors’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-388
Closed -$400 – 1915
2024
Q4 		$400 Buy
+388
New +$417 ﹤0.01% 1832

Other funds holding CTMX

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bell Investment Advisors's CTMX Position: Q1 2025 in Review

Bell Investment Advisors sold out of CytomX Therapeutics (CTMX) in Q1 2025, closing a stake of 388 shares — an estimated $400 sold.

Bell Investment Advisors first reported a position in CTMX in Q4 2024 and held it in 1 quarter. The position peaked at $400 in Q4 2024. 66 funds tracked by Wall St. Rank hold CTMX as of Q1 2025.

  • Bell Investment Advisors reported no remaining CytomX Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Bell Investment Advisors sold 388 CytomX Therapeutics shares in Q1 2025, an estimated $400.
  • Bell Investment Advisors first reported a position in CytomX Therapeutics in Q4 2024 and held it in 1 quarter.
  • Bell Investment Advisors's CytomX Therapeutics position peaked at $400 in Q4 2024.
  • 66 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q1 2025.

Based on Bell Investment Advisors's 13F filing for Q1 2025, filed 16 May 2025.